search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR study


- candidate number25557
- NTR NumberNTR6308
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR21-nov-2016
- Secondary IDs2016.221  METC VUMC
- Public TitleA phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR study
- Scientific TitleA phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR study
- ACRONYMthe STELLAR study
- hypothesisSunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine.
- Healt Condition(s) or Problem(s) studiedGlioblastoma multiforme
- Inclusion criteria1. Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
2. Histologically confirmed de novo or secondary glioblastoma with unequivocal first progression, at least 3 months off radiotherapy.
3. No more than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks prior to randomization.
4. Patients may have undergone surgery for recurrence. If operated, residual and measurable disease after surgery is not required but surgery must have confirmed the recurrence.
5. No radiotherapy, stereotactic radiosurgery or brachytherapy as treatment for recurrence.
6. Patients must have a Karnofsky Performance Score 70%
7. Patients need to have adequate hematological, renal and hepatic function as assessed by the following laboratory requirements to be conducted within seven days prior to start study treatment:
a. Hemoglobin 7.0 mmol/L
b. Absolute neutrophil count (ANC) 1.5 x 109/L
c. Platelet count 100 x 109/L
d. ALAT and ASAT 2.5 x ULN
e. Serum creatinine eGFR 50 ml/min
f. Albumin 25 g/L
8. Age 18 years
9. Male and female patients with reproductive potential must use an approved contraceptive method during and for three months after discontinuation of study treatment.
10. Patients must be able to swallow oral medication.
- Exclusion criteria1. Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
2. Patients with a prior (< 5 years) or concomitant second malignancy.
3. Prior radiotherapy in the abdomen or in the lungs or in more than 3 vertebrae in the spine (Less than 3 vertebrae are considered a small radiation field and eligibility will be decided on an individual basis from the PI)
4. Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be 160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
5. Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds.)
6. Initial MR-scan of the brain showing intratumoral hemorrhage, except for stable post-operative grade 1 hemorrhage.
7. Known hypersensitivity to sunitinib or to its excipients.
8. Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patients compliance.
9. Use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic (as opposed to prophylactic) purposes.
10. Drug or alcohol abuse.
11. Females who are pregnant or breast-feeding.
12. Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications.
13. Unwillingness or inability to comply with study and follow-up procedures.
14. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-dec-2016
- planned closingdate1-dec-2019
- Target number of participants100
- InterventionsGroup 1 (experimental arm): Sunitinib, 300 mg administered orally in a weekly schedule.

Group 2 (control arm): Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
- Primary outcomeTo determine the effect of high-dose sunitinib versus standard treatment with lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria.
- Secondary outcome- To determine the effect of high-dose sunitinib on overall survival (OS 9, OS 12) in patients with recurrent GBM.
- To assess the objective radiological response rate, using the RANO criteria.
- To assess the safety and toxicity during treatment, using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.
- To assess patient-oriented criteria: steroid use and health-related quality of life (reported by patients and caregivers/relatives).
- To explore the potential value of blood markers for molecular diagnostics, disease and response monitoring.
- To explore if MGMT promoter methylation status modulates the response to sunitinib.
- TimepointsDisease will be assessed by MRI according to an uniform neuro-oncology protocol every 6 weeks for the first 6 months and every 12 weeks until documented progression. Safety profile of both treatment strategies will be assessed separately for each cycle of therapy and every 12 weeks after the end of treatment if adverse effects have not resolved or are newly emerging. Furthermore, quality of life assessment takes place every 6 weeks using questionnaires.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDrs. C.G. Brahm
- CONTACT for SCIENTIFIC QUERIESDrs. C.G. Brahm
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
VU University Medical Center
- Publications
- Brief summaryStudy design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM.

Hypothesis: Sunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine.

Study population: Adult patients with recurrent GBM.

Primary objective:
 To determine the effect of high-dose sunitinib versus lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria.

Secondary objectives:
 To determine the effect of high-dose sunitinib on overall survival (OS 9, OS 12) in patients with recurrent GBM.
 To assess the objective radiological response rate, using the RANO criteria.
 To assess toxicity, using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.
 To assess patient-oriented criteria: steroid use and health-related quality of life (reported by patients and caregivers/relatives).
 To explore the potential value of blood markers for molecular diagnostics, disease and response monitoring.
 To explore if MGMT promoter methylation status modulates the response to sunitinib.

Treatment: After randomization, 100 patients will be divided equally over two treatment groups and will receive:
Group 1 (experimental arm): Sunitinib, 300 mg administered orally in a weekly schedule.
Group 2 (control arm): Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.

Disease will be assessed by MRI according to an uniform neuro-oncology protocol every 6 weeks for the first 6 months and every 12 weeks until documented progression. Safety profile of both treatment strategies will be assessed separately for each cycle of therapy and every 12 weeks after the end of treatment if adverse effects have not resolved or are newly emerging. Furthermore, quality of life assessment takes place every 6 weeks using questionnaires.
- Main changes (audit trail)
- RECORD21-nov-2016 - 19-mei-2017


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl